Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | RARA | P10276 | 6/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.49 |
| ▸ | IKBKB | O14920 | 3/20 | 0.49 |
| ▸ | NR0B2 | Q15466 | 1/20 | 0.49 |
| ▸ | RARG | P13631 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14983842 | 0.86 | RARB (0.54) | RARBHDAC11HDAC2HDAC3HDAC4 | |
| SCHEMBL12531334 | 0.85 | RARB (0.76) | RARBHDAC11HDAC2HDAC3HDAC4 | |
| SCHEMBL5828190 | 0.84 | RARB (0.70) | RARBHDAC11HDAC2HDAC3HDAC4 | |
| SCHEMBL178029 | 0.81 | RARB (0.64) | RARBHDAC11HDAC2HDAC3HDAC4 | |
| SCHEMBL12531342 | 0.80 | RARB (0.56) | RARBHDAC11HDAC2HDAC3HDAC4 | |
| SCHEMBL6449257 | 0.79 | RARB (0.38) | RARBHDAC11HDAC2HDAC3HDAC4 | |
| SCHEMBL6620246 | 0.79 | IKBKB (0.54) | RARBHDAC11HDAC2HDAC3HDAC4 | |
| SCHEMBL6619759 | 0.79 | RARB (0.59) | RARBHDAC11HDAC2HDAC3HDAC4 | |
| SCHEMBL12531381 | 0.78 | RARB (0.53) | RARBHDAC11HDAC2HDAC3HDAC4 | |
| SCHEMBL14974800 | 0.77 | RARA (0.52) | RARBHDAC11HDAC2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153875-B2 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE SAN DIEGO (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1385465-A4 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | INCYTE SAN DIEGO INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | INCYTE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| EP-1463718-A1 | 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER | Incyte San Diego Incorporated (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004066952-A2 | BENZOXAZOLE, BENZOTHIAZOLE, AND BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER DISEASES | INCYTE CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | INCYTE SAN DIEGO INCORPORATED | 2004-05-20 | — | — | US | disclosed |
| EP-1385465-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | Incyte San Diego, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003050098-A1 | 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER | INCYTE SAN DIEGO INCORPORATED (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE GENOMICS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002072009-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | MAXIA PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | AR, CCNT1, BRD1 | RARB 401/4885HDAC11 14/4885HDAC2 46/4885 |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | CCNY, HRAS, AHR | RARB 1465/4885HDAC11 48/4885HDAC2 490/4885 |
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | PTPA, PTPRC, PTPRCAP | RARB 2680/4885HDAC11 320/4885HDAC2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.